HOME > ARCHIVE
ARCHIVE
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 6, 2003
- Teijin Pharma Forecasts Major Growth in 2005, 2006
October 6, 2003
- MEDICAL DEVICE NEWS IN BRIEF
October 6, 2003
- 1st Drug Therapy for Internal Hemorrhoids Expected in FY2004: Lequio, MPC
October 6, 2003
- Takara Bio Develops High Precision Monitoring Method for Inserted Genes
October 6, 2003
- PBI to Begin Full-scale Contract Manufacture of Antibody Drugs
October 6, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
October 6, 2003
- Physicians Trust Viagra Based on Evidence: Pfizer
October 6, 2003
- PRESS SEMINAR
October 6, 2003
- AnGes MG Pursuing Alliance Strategy: Prof. Morishita
October 6, 2003
- Otsuka: WATER (18O, 95%) CIL for PET
October 6, 2003
- New Relief Measures Planned for Developing Countries: JPMA
October 6, 2003
- Japanese Healthcare Q&A (1)
October 6, 2003
- BUSINESS NEWS IN BRIEF
October 6, 2003
- WEBSITE NEWS
October 6, 2003
- Chuikyo Starts Discussion to Review NHI Pricing Rule
October 6, 2003
- PFSB to Beef Up NDA Review, Safety Measures, Victim Relief via New Drug Organization
October 6, 2003
- Sanwa Kagaku Kenkyusho: Glutest Neo Blood Glucose Meter
October 6, 2003
- Revisions of Package Inserts Required for 16 Drugs, Including Ribavirin
October 6, 2003
- BULLETIN
October 6, 2003
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
